202 related articles for article (PubMed ID: 20142302)
1. Central nervous system effects of haloperidol on THC in healthy male volunteers.
Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
[TBL] [Abstract][Full Text] [Related]
2. Effect of intrapulmonary tetrahydrocannabinol administration in humans.
Zuurman L; Roy C; Schoemaker RC; Hazekamp A; den Hartigh J; Bender JC; Verpoorte R; Pinquier JL; Cohen AF; van Gerven JM
J Psychopharmacol; 2008 Sep; 22(7):707-16. PubMed ID: 18515447
[TBL] [Abstract][Full Text] [Related]
3. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
[TBL] [Abstract][Full Text] [Related]
4. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
[TBL] [Abstract][Full Text] [Related]
5. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
[TBL] [Abstract][Full Text] [Related]
6. Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids.
Strougo A; Zuurman L; Roy C; Pinquier JL; van Gerven JM; Cohen AF; Schoemaker RC
J Psychopharmacol; 2008 Sep; 22(7):717-26. PubMed ID: 18583433
[TBL] [Abstract][Full Text] [Related]
7. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers.
Kaufmann RM; Kraft B; Frey R; Winkler D; Weiszenbichler S; Bäcker C; Kasper S; Kress HG
Pharmacopsychiatry; 2010 Jan; 43(1):24-32. PubMed ID: 20178093
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.
Curran HV; Brignell C; Fletcher S; Middleton P; Henry J
Psychopharmacology (Berl); 2002 Oct; 164(1):61-70. PubMed ID: 12373420
[TBL] [Abstract][Full Text] [Related]
9. Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?
Kleinloog D; Liem-Moolenaar M; Jacobs G; Klaassen E; de Kam M; Hijman R; van Gerven J
J Psychopharmacol; 2012 Oct; 26(10):1307-16. PubMed ID: 22596206
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.
Zuurman L; Roy C; Schoemaker RC; Amatsaleh A; Guimaeres L; Pinquier JL; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Mar; 24(3):363-71. PubMed ID: 18801827
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.
de Haas SL; Franson KL; Schmitt JA; Cohen AF; Fau JB; Dubruc C; van Gerven JM
J Psychopharmacol; 2009 Aug; 23(6):625-32. PubMed ID: 18635696
[TBL] [Abstract][Full Text] [Related]
12. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment.
Ramaekers JG; Moeller MR; van Ruitenbeek P; Theunissen EL; Schneider E; Kauert G
Drug Alcohol Depend; 2006 Nov; 85(2):114-22. PubMed ID: 16723194
[TBL] [Abstract][Full Text] [Related]
13. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
Müller-Vahl KR; Koblenz A; Jöbges M; Kolbe H; Emrich HM; Schneider U
Pharmacopsychiatry; 2001 Jan; 34(1):19-24. PubMed ID: 11229617
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
[TBL] [Abstract][Full Text] [Related]
15. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.
D'Souza DC; Braley G; Blaise R; Vendetti M; Oliver S; Pittman B; Ranganathan M; Bhakta S; Zimolo Z; Cooper T; Perry E
Psychopharmacology (Berl); 2008 Jul; 198(4):587-603. PubMed ID: 18228005
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users.
Ramaekers JG; Kauert G; Theunissen EL; Toennes SW; Moeller MR
J Psychopharmacol; 2009 May; 23(3):266-77. PubMed ID: 18719045
[TBL] [Abstract][Full Text] [Related]
17. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
D'Souza DC; Abi-Saab WM; Madonick S; Forselius-Bielen K; Doersch A; Braley G; Gueorguieva R; Cooper TB; Krystal JH
Biol Psychiatry; 2005 Mar; 57(6):594-608. PubMed ID: 15780846
[TBL] [Abstract][Full Text] [Related]
18. Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers.
Dumont GJ; van Hasselt JG; de Kam M; van Gerven JM; Touw DJ; Buitelaar JK; Verkes RJ
J Psychopharmacol; 2011 Apr; 25(4):478-89. PubMed ID: 20817749
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
[TBL] [Abstract][Full Text] [Related]
20. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.
Englund A; Atakan Z; Kralj A; Tunstall N; Murray R; Morrison P
J Psychopharmacol; 2016 Feb; 30(2):140-51. PubMed ID: 26577065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
